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Cerebral malaria is associated with decreased production of nitric oxide and decreased levels of its precur-
sor, L-arginine. Abnormal amino acid metabolism may thus be an important factor in malaria pathogenesis.
We sought to determine if other amino acid abnormalities are associated with disease severity in falciparum
malaria. Subjects were enrolled in Dar es Salaam, Tanzania (children) (n  126), and Papua, Indonesia
(adults) (n  156), in two separate studies. Plasma samples were collected from subjects with WHO-defined
cerebral malaria (children), all forms of severe malaria (adults), and uncomplicated malaria (children and
adults). Healthy children and adults without fever or illness served as controls. Plasma amino acids were
measured using reverse-phase high-performance liquid chromatography with fluorescence detection. Several
plasma amino acids were significantly lower in the clinical malaria groups than in healthy controls. Despite the
differences, phenylalanine was the only amino acid with mean levels outside the normal range (40 to 84 M)
and was markedly elevated in children with cerebral malaria (median [95% confidence interval], 163 [134 to
193] M; P< 0.0001) and adults with all forms of severe malaria (median [95% confidence interval], 129 [111
to 155] M; P < 0.0001). In adults who survived severe malaria, phenylalanine levels returned to normal, with
clinical improvement (P  0.0002). Maintenance of plasma phenylalanine homeostasis is disrupted in severe
malaria, leading to significant hyperphenylalaninemia. This is likely a result of an acquired abnormality in the
function of the liver enzyme phenylalanine hydroxylase. Determination of the mechanism of this abnormality
may contribute to the understanding of neurological complications in malaria.
The coma of cerebral malaria (CM) is frequently accompa-
nied by seizures and abnormalities of muscle tone and posture
(23). The mechanisms of these neurological complications are
unclear; however, cerebral ischemia is unlikely to be the sole
explanation, as survivors are usually neurologically intact (17).
Altered amino acid metabolism in response to malaria infec-
tion may contribute to disease severity. Circulating amino acids
serve primarily as substrates for protein synthesis, metabolic
energy (oxidation through the carboxylic acid cycle), or glu-
coneogenesis and ketogenesis. Importantly, certain amino ac-
ids are also substrates for neurochemical mediators, which can
be increased by inflammatory stimuli. For example, gamma
interferon increases metabolism of tryptophan through the
kynurenine pathway, resulting in the production of the excita-
tory mediators quinolinic acid, kynurenic acid, and picolinic
acid. These have been investigated as possible contributors to
the neurologic dysfunction of CM (15).
We have previously shown that plasma levels of the nitric
oxide (NO) precursor L-arginine were significantly reduced in
African children with CM relative to levels in healthy controls
(HC) and those with uncomplicated malaria (UM) (14). In
addition, case fatality rates from CM were independently as-
sociated with the degree of hypoargininemia. These results
paralleled previous work demonstrating similarly reduced sys-
temic levels of NO metabolites and NO synthase expression in
blood mononuclear cells from children with CM relative to
those of patients with UM and controls (1). In extending our
amino acid analysis from those previous studies, we discovered
abnormalities in plasma phenylalanine levels in children with
malaria. Additionally, we measured phenylalanine levels in
plasma collected from Indonesian adults with severe malaria
(SM) and UM. Here, we describe our findings and discuss how
they may relate to the neurological complications of CM.
MATERIALS AND METHODS
Subjects. Plasma samples analyzed in this study were collected from a previous
study of NO and malaria involving children aged between 6 months and 7 years
from Dar es Salaam (1), Tanzania. Since publishing plasma arginine levels in
Tanzanian children with malaria (14), we have located additional stored plasma
samples (19 HC, 19 UM, and 13 CM samples) from the original cohort of
children (1). These samples were included for analysis in the present study.
* Corresponding author. Mailing address: 30 North 1900 East, Room
4B319, Salt Lake City, UT 84132. Phone: (801) 585-2867. Fax: (801)
585-3377. E-mail: bert.lopansri@hsc.utah.edu.
3355
 o
n
 N
ovem
ber 10, 2013 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
Reanalysis of arginine levels including the recently located samples does not
change any interpretation made in the previous publication (14). However, for
the total number of samples now available, the mean arginine level for HC
children was significantly less (122 versus 103 M), as was the mean arginine
level for subjects UM (70 versus 56 M). The mean arginine levels for children
with CM (45.4 versus 45 M) and the statistical association between plasma
arginine concentration and case fatality remain unchanged. Amino acids were
also measured in plasma collected from Indonesian adults, aged 14 to 60 years,
in Papua, Indonesia. Study subjects had been enrolled in the following groups: (i)
CM (children) and SM (adults), defined using modified WHO criteria (20); (ii)
UM (children and adults) (1); and (iii) HC (adults and children) (1, 2). Plasma
samples were collected upon enrollment in the study and were stored at 80°C.
Some adults had received quinine prior to enrollment, and the duration of
quinine therapy prior to sample collection was recorded. A second plasma
sample was collected from adult SM survivors 3 days after enrollment but was
unavailable for children and adults who died with SM (all deaths occurred within
the first 3 days). All patients diagnosed with CM or SM were managed according
to national protocols and treated with intravenous quinine. Institutional review
board approval was given for the study, and informed consent was obtained from
participants or their guardians.
Analytical methods. Samples were prepared as described previously (14) and
derivatized with AccQFluor Reagent (Waters Corp.) according to the manufac-
turer’s recommendations. A standard curve was prepared in a similar fashion.
Alpha-aminobutyric acid was used as an internal control. Ten microliters of
derivatized sample was used to quantify amino acid levels using reverse-phase
high-performance liquid chromatography (HPLC) with gradient conditions and
fluorescence detection. Three solutions were used to generate the gradient at a
flow rate of 1 ml/minute: solution A (AccQFluor Eluent A [Waters Corp.]),
solution B (100% HPLC-grade acetonitrile), and solution C (double-deionized
water). The gradient was generated according to the manufacturer’s recommen-
dations (Waters Corp.). Intra-assay variability was 0.65%, and interassay vari-
ability was 1.4%. With this method, we were able to quantify levels of basic amino
acids (arginine, ornithine, and lysine), aromatic amino acids (phenylalanine and
tyrosine), and neutral amino acids (histidine, leucine, and isoleucine). There was
no difference in the phenylalanine levels of HC adults and those of HC children;
therefore, the normal range for plasma phenylalanine was generated by combin-
ing all HC data from Tanzanian and Indonesian groups and is based on the
mean  2 standard deviations. For phenylalanine, this range was 40 to 84 M.
The normal ranges generated by our method conformed closely to those estab-
lished by the Biochemical Genetics Section, ARUP Laboratories, University of
Utah, where analysis was performed using ion-exchange chromatography with
detection using spectrophotometry after a reaction with ninhydrin. The small
volumes of plasma available from the majority of our subjects precluded amino
acid analysis by this method. Plasma samples from healthy Caucasians and study
subjects with sufficient volume were analyzed both by our method and at the
Biochemical Genetics Section, ARUP Laboratories, University of Utah. Reli-
ability, denoted R, between the two amino acid assays was calculated using the
intraclass correlation coefficient. In the calculation, the assay method was con-
sidered a fixed effect, since inference applies only to these two specific methods
(8). A generally accepted rule of thumb for interpreting the reliability coefficient
is as follows: R  0.4 represents poor reliability, 0.4  R  0.75 represents fair
to good reliability, and R  0.75 represents excellent reliability. The reliability
coefficients between the two amino acid assays were as follows: phenylalanine, R 
0.99; tyrosine, R  0.84; arginine, R  0.77; ornithine, R  0.81; lysine, R  0.71;
histidine, R  0.55; leucine, R  0.70; and isoleucine, R  0.66, all of which are
acceptable levels of reliability. Based on these results, we were confident in using
HPLC for amino acid analysis.
Statistical methods. Fisher’s exact test was used to compare proportions.
Continuous variables were compared using an independent-groups t test if nor-
mality assumptions were met; otherwise, groups were compared using the Mann-
Whitney U test. Longitudinal data were analyzed using a paired t test. Multiple
linear regression was used to control for confounding variables. Variables with
extreme skewness or kurtosis were log transformed to meet the normality as-
sumption for use in these linear regression models. All statistical analyses were
performed using Stata 8.0 software. P values of 0.05 were considered to be
statistically significant.
RESULTS
Of the 191 children in the original Tanzanian study (1), 126
(38/50 [76%] HC, 36/55 [65%] with UM, and 52/86 [60%] with
CM) had a sufficient amount of plasma available for amino
acid analysis. Of the 52 children with CM in this study, 20 died
and 32 survived (38% case fatality). The case fatality in the
original study was 30% (26/86) (1). Patient characteristics were
published previously (1, 14) and are listed in Table 1 for our
subset. Fourteen children with CM had concomitant severe
malarial anemia, but none had acute renal failure. In a sepa-
rate study of Indonesian adults with SM, plasma samples from
156 adults (43 HC, 43 UM, and 70 SM samples) were available
for sampling. Adult patient characteristics at enrollment are
listed in Table 2. In the SM group, 57 survived and 13 died.
Fifty-eight percent of adults presenting with SM had CM,
34.3% had renal failure, and 2.7% had severe anemia. Seven
(9.6%) patients with SM had both renal failure and CM, five
(71%) of whom died. No deaths occurred in either adult or
childhood UM groups.
TABLE 1. Characteristics of subjects in Tanzanian study groups
upon enrollmenta
Variable HC (n  38) UM (n  36) CM (n  51)
Age (yr) 4.6 2.3 3.4 2.0 3.6 1.9
% Male 63 56 53
Wt (kg) 15.0 4.8 12.5 3.8 12.6 3.5
Time since last
meal (h)
12.6  1.1 7.1 10 15.8 13.6
White blood cell
count (103/l)
8.1  1.9 11.1 5.5 17.0 10.6
Hemoglobin level
(g/liter)
11.0  1.6 7.4 2.3 6.3 2.2
Plasma creatinine
level (mol/liter)
36.3  10.4 37.6 8.9 61.7 35
Geometric mean
parasitemia
(trophozoites/l)
328b 55,872 35,789
a Data are presented as means  standard deviations, except for parasitemia.
b Refers to those with asymptomatic parasitemia (n  5).
TABLE 2. Characteristics of adult subjects in Indonesian study
groups upon enrollmenta
Variableb HC (n  43) UM (n  43) SM (n  70)
Age (yr) 27.4  10.1 29.3  9.3 26.7  9.4
Wt (kg) 56.1  7.2 56.6  8.7 54.4  8.1
% Male 50 64 82
White cell count
(109/liter)
7.6  2.8 7.2  7.7 9.0  4.1
Hb (g/dl) 12.9  3.0 12.8  1.9 9.6  3.0
Plasma creatinine level
(mol/liter)
77.2  13.0 89.8  16.1 270.4  266.2
Time from last meal (h) 12.0  0.3 11.3  5.7 16.5  14.8
Chloroquine use prior
to study enrollment
[no. of patients (%)]
23 (53) 28 (40)
Duration of quinine
treatment prior to
enrollment (h)
0 3.1 5.3 9.1  11.6
ALT level (U/liter) 15.9  6.3 29.4  27.2 46  37.7
HCO3 level (mmol/liter) 28.8  1.7 25.2  2.2 25.4  5.1
Geometric mean
parasitemia
(trophozoites/l)
149c 4,136 10,605
a All values represent means  standard deviations, except for parasitemia.
b Hb, hemoglobin; ALT, alanine aminotransferase.
c Applies only to those with asymptomatic parasitemia.
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In addition to decreased arginine levels relative to controls
reported previously (14), in children, there were statistically
significant decreases in ornithine, lysine, and histidine levels in
all clinical malaria groups compared to levels in HC (Table 3).
Despite significant differences, the mean plasma levels of these
amino acids were within the normal ranges established for
screening for inherited metabolic diseases in children. By con-
trast, phenylalanine was the only elevated amino acid in the
malaria groups, with the mean greater than the upper limit of
the normal range (Fig. 1 and Table 3). The proportion of
children with abnormal phenylalanine levels was significantly
greater in the CM group (49/52 [94%]) than in the UM group
(27/36 [75%]) (P  0.013). Likewise, the proportions in adults
with hyperphenylalaninemia was higher in the SM group
(53/70 [76%]) than in the UM group (19/43 [44%]) (P 
0.001). In contrast, only 2 of 38 HC children and 0/43 HC
adults had elevated phenylalanine levels. The degree of hyper-
phenylalaninemia correlated with disease severity, with levels
in CM and SM groups significantly greater than those in the
respective HC and UM groups (Fig. 1a and b). This association
remained after controlling for age, weight, duration of fasting,
use of chloroquine prior to admission, duration of quinine use
prior to sample collection, biochemical hepatitis, and renal
function using linear regression. There was no association be-
tween phenylalanine levels and CM case fatality in children;
FIG. 1. Plasma phenylalanine concentrations in severe malaria. (a) Day 0 levels in Tanzanian children with CM. (b) Day 0 levels in Indonesian
adults with SM. (c) Day 0 levels in Indonesian adults by outcome, death (median [95% confidence interval], 275 [163 to 399] M) versus survival
(median [95% confidence interval], 118 [90 to 140] M). (d) Longitudinal data for Indonesian adults on day 0 (median [95% confidence interval],
116 [86 to 133] M) and day 3 (median [95% confidence interval], 76 [70 to 90] M) of the study. Box plot, median and interquartile range; whiskers,
maximum/minimum range; dotted lines, phenylalanine means  2 standard deviations (normal range) based on 80 HC samples. Differences between
means were compared using a Wilcoxon-Mann-Whitney test. Longitudinal data were compared using a paired two-tailed t test.
TABLE 3. Plasma amino acid levels in Tanzanian childrena
Amino acid
Mean amino acid level (M)  SD
Normal rangeb HC (n  38) UM (n  36) CM (n  52)
Phenylalanine 30–80 61 13 118 52c 177  81c,d
Tyrosine 30–120 50 10 53 13 85 47c,d
Phe/Tyr ratio 1.3 0.32 2.4 1.2c 2.2  0.9c
Arginine 40–160 100 32 56 22c 45  15c
Ornithine 20–135 64 24 37 15c 34  12c
Lysine 80–250 151 31 94 28c 108  47c
Histidine 50–130 80 25 61 18c 65  20c
Leucine 60–230 116 36 118 51 139 41c,d
Isoleucine 30–130 63 20 71 38 54 18
a Groups compared using Wilcoxon-Mann-Whitney test with significance de-
fined as a P value of 0.013, given multiple groups.
b Normal range as established by the Biochemical Genetics Section, ARUP
Laboratories, University of Utah.
c Significantly different from HC (P  0.013).
d CM significantly different from UM (P  0.013).
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however, levels were higher in SM case fatalities than in sur-
vivors (Fig. 1c). Phenylalanine levels did not differ between
adults with CM and those with other forms of SM or between
adults with and without renal failure. Phenylalanine levels were
significantly decreased by day 3 of treatment in SM survivors
but did not completely normalize (Fig. 1d). Hyperphenylala-
ninemia was not correlated with coma score in children with
CM or in adults with SM.
Tyrosine, the single, immediate product of phenylalanine
metabolism by hepatic phenylalanine hydroxylase, was in-
creased in CM (Table 3) and SM (mean  SD, 81  46 M)
groups only. The significance of this finding is unclear, as
tyrosine levels in CM and SM groups were within the normal
range. Moreover, provoked hyperphenylalaninemia in healthy
adults leads to a mild elevation of plasma tyrosine levels (19).
To better define the mechanism of hyperphenylalaninemia, we
calculated the phenylalanine/tyrosine ratio, a sensitive measure
of phenylalanine hydroxylase activity. This ratio has been used
for the detection of heterozygous carriers of phenylketonuria
mutant genes (9), as impairment of phenylalanine hydroxylase
leads to ratios above normal (0.8 to 1.2) (3). The phenylala-
nine/tyrosine ratio was increased in all groups with clinical
malaria but was not different between mild and severe disease
(Table 3). This was due in part to increases in plasma tyrosine
levels in the CM and SM groups.
DISCUSSION
The causes and sequelae of chronic hyperphenylalaninemia
have been well characterized in children with inborn errors of
phenylalanine metabolism. However, less is known about the
physiologic consequences of acute perturbations in phenylala-
nine metabolism, especially in infectious diseases. Hyperphe-
nylalaninemia and an elevated phenylalanine/tyrosine ratio in
children with falciparum malaria have been observed in one
previous study in which four children with CM had elevated
phenylalanine concentrations (7) similar to the levels we mea-
sured. Inhibition of phenylalanine metabolism has also been
reported in sepsis of various etiologies (4, 6, 21) but to a lesser
degree than that observed in CM. Despite these observations,
the mechanism by which hyperphenylalaninemia develops in
acute infections has not been established. Release of phenyl-
alanine into the circulation from skeletal muscle catabolism
may be an important factor. Under normal circumstances, ex-
cess phenylalanine (e.g., phenylalanine loading test) leads to
substrate-level regulation of hepatic phenylalanine hydroxylase
activity with consequent lowering of plasma phenylalanine lev-
els within a narrow range (40 to 84 M). This enzyme converts
phenylalanine to tyrosine in an oxygen- and pterin-dependent
reaction (Fig. 2). The elevated phenylalanine/tyrosine ratio in
malaria suggests that hyperphenylalaninemia results from im-
paired phenylalanine hydroxylase activity in the liver.
Hyperphenylalaninemia in malaria may have important
physiologic consequences. Two examples come from inborn
errors affecting aromatic amino acid metabolism (e.g., phe-
nylketonuria and dopamine-responsive dystonia [DRD]) that
lead to neurological abnormalities. These genetic diseases im-
pair phenylalanine hydroxylase activity by different mecha-
nisms, and both cause chronic neurological disease in children.
Phenylketonuria arises from inherited mutations in the phe-
nylalanine hydroxylase gene that lead to persistent elevations
in plasma phenylalanine levels up to 50 times greater than
normal. High concentrations of plasma phenylalanine lead to
phenylalanine accumulation in the brain, which is neurotoxic
(12). In contrast, DRD is caused by a tetrahydrobiopterin
deficiency from loss-of-function mutations in the GTP cyclo-
hydrolase gene, the rate-limiting enzyme for tetrahydrobio-
pterin biosynthesis. Tetrahydrobiopterin is a required cofactor
not only for phenylalanine hydroxylase but also for other en-
zymes (i.e., neuronal NO synthase, tryptophan hydroxylase,
tyrosine hydroxylase, and dopamine -hydroxylase) essential
for brain neurotransmitter biosynthesis (16) (Fig. 2). DRD
manifests with mild hyperphenylalaninemia, decreased mono-
amine neurotransmitter metabolite levels in the spinal fluid,
and neurological dysfunction independent of plasma phenylal-
anine levels (18).
An underlying genetic phenylalanine hydroxylase abnormal-
ity as a cause of hyperphenylalaninemia in malaria is unlikely,
since we would not have expected a rapid correction of plasma
phenylalanine levels and the phenylalanine/tyrosine ratio (data
not shown) upon clinical improvement with conventional treat-
ment. Moreover, the degree of hyperphenylalaninemia that we
observed in malaria is not consistent with the extreme eleva-
tions seen in phenylketonuria. Given the phenotypic similari-
ties between children with DRD and children with CM (e.g.,
somnolence, recurrent seizures, motor dystonia, abnormal pos-
turing, and autonomic instability) (18), we favor an acquired
tetrahydrobiopterin deficiency as a more plausible explanation
for hyperphenylalaninemia in malaria.
There is minimal passage of tetrahydrobiopterin across the
blood-brain barrier (13). Thus, neurotransmitter production
requires local de novo synthesis of this cofactor. Brain tetra-
FIG. 2. Relationship of tetrahydrobiopterin-dependent aromatic
amino acid metabolism to biogenic amine neurotransmitter synthesis.
The plasma concentration of L-phenylalanine is regulated by changes
in the activity of hepatocyte phenylalanine hydroxylase (PAH). Phe-
nylalanine hydroxylase activity depends in part on hepatocyte synthesis
of its obligatory cofactor, tetrahydrobiopterin (BH4). Tyrosine, the
phenylalanine hydroxylase reaction product, enters the blood and is
taken up by neurons for further synthesis to L-DOPA (3,4-dihydroxy-
phenylalanine) by tyrosine hydroxylase (TH), another BH4-dependent
enzyme. L-DOPA serves as the precursor for synthesis of several bio-
genic amine neurotransmitters (dopamine, norepinephrine, and epi-
nephrine), beginning with the enzyme L-amino acid decarboxylase
(ADCC).
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hydrobiopterin deficiency in CM, but not UM, is a possible
explanation for the absence of neurological symptoms in indi-
viduals with UM and hyperphenylalaninemia. Tetrahydrobio-
pterin levels have been measured in the spinal fluid of African
children with CM in two separate studies, revealing conflicting
results. One study of Zambian children with CM revealed
that low total biopterin (biopterin, dihydrobiopterin, and tetra-
hydrobiopterin) in cerebral spinal fluid correlated with deep
coma (22). Another study in coastal Kenya reported elevated
tetrahydrobiopterin levels in subjects with CM that were more
than 10 times higher than those measured in Zambian children
(5). The discrepant results highlight the difficulties in measur-
ing biopterin metabolites in biologic fluids (10), especially in
clinical studies of malaria in developing countries (11). Hence,
whether systemic and/or central nervous system tetrahydro-
biopterin deficiency is present in malaria remains an open
question.
In conclusion, we have shown that children with CM and
adults with all forms of SM have disordered phenylalanine
metabolism, which may result from impaired hepatic phenyl-
alanine hydroxylase activity. Whether hyperphenylalaninemia
is associated with brain neurotransmitter and pterin abnormal-
ities in CM has therapeutic implications (such as adjunctive
tetrahydrobiopterin replacement therapy) and warrants fur-
ther investigation.
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